저자의 연구 키워드

저자의 연구 키워드

#5-HT3 receptor antagonist

#위암

#전이

#항암화학요법

#Adenoid cystic carcinoma

#Adjuvant chemoradiotherapy

#Adjuvant chemotherapy

#Administration

#Anthracycline

#Antiemetics

#Antineoplastic agents

#Antitumor

#Awareness

#Axitinib

#bcl-2

#Belotecan

#Benign

#Biliary tract neoplasms

#Blood platelets

#Breast Neoplasms

#CA 19-9 antigen

#Capecitabine

#Carcinoembryonic antigen

#CD56

#Chemoradiotherapy

#Chemotherapy

#Cisplatin

#CKD-516

#Clinical Trial

#Colorectal neoplasms

#Cyclooxygenase 2

#Diabetes mellitus

#Distal cholangiocarcinoma

#DLC1 protein

#Dolasetron mesylate

#Drug Screening Assays

#Drug therapy

#ErbB receptors

#Fluorescence

#FOLFIRI

#Gastric Cancer

#GC1118

#Gemcitabine

#genetic

#Genetic polymorphism

#Genexol

#HER2

#histone deacetylases

#human

#Immunohistochemistry

#In Situ Hybridization

#Interleukin-1beta

#Irinotecan

#Ki-67

#KX-01

#Leptomeningeal Metastases

#Leukocytes

#Lymphoma

#Mediastinal lymph node

#Metformin

#Microsatellite instability

#Microtubules

#Mitotic catastrophe

#Monoclonal antibody

#Natural killer cells

#Nausea

#Neoadjuvant therapy

#Neoplasm metastasis

#Neoplasms

#Non-small cell lung carcinoma

#Non-small cell lung neoplasm

#Obesity

#Observational study

#Ondansetron

#OPB-31121

#Oral

#Oxaliplatin

#p300-CBP transcription factors

#p53

#Paclitaxel

#Pancreatectomy

#Pancreatic neoplasms

#Pancreaticoduodenectomy

#Patients

#Perception

#P-glycoprotein

#Pharmacokinetics

#Phase 1

#Phase I

#Phase I clinical trial

#Prevention

#Prognosis

#Prognostic Factor

#promoter regions

#Public health

#Pulmonary nodule

#Republic of Korea

#Resource use

#RNA stability

#Sensitivity and Specificity

#Sinusoidal obstruction syndrome

#Skin

#Smad3

#Solid tumor

#Sp1 transcription factor

#Splenic artery

#Splenomegaly

#Src kinase inhibitor

#STAT3

#STAT3 inhibitor

#Stomach cancer

#Stomach neoplasms

#Synergism

#Taxane

#Therapeutic Use

#Transforming growth factor beta

#Transforming growth factor beta1

#Trastuzumab

#Treatment patterns

#trichostation A

#Triple negative breast neoplasms

#Tristetraprolin

#Tumor biomarker

#Vascular disrupting agent

#Vascular endothelial growth factor

#Vinorelbine

#Volition

#Vomiting